Description
The skeptic noted that most circadian studies use developmental knockouts, but therapeutic timing in adults may yield different results due to compensatory mechanisms and tissue maturation. This timing-dependent efficacy gap is critical for translating circadian research to clinical interventions.
Source: Debate session sess_SDA-2026-04-10-SDA-2026-04-08-gap-debate-20260406-062033-16eccec1 (Analysis: SDA-2026-04-08-gap-debate-20260406-062033-16eccec1)
Resolution criteria
Resolution requires: (1) comparative transcriptomic and behavioral analysis of adult (>=3 months) vs developmental (embryonic or neonatal) circadian gene knockout or overexpression mice (Bmal1, Clock, Per1/2, Cry1/2), measuring clock gene expression and cognitive performance in Morris water maze and novel object recognition; (2) pharmacologic circadian modulation (REV-ERB agonists, ROR agonists) administered to adult vs aged mice (>=12 months), measuring whether adult-onset produces comparable cognitive benefits to developmental manipulation; (3) circadian transcriptomics of human neurons or brain organoids from adult vs fetal sources, comparing clock gene network topology. Developmental models alone cannot establish adult therapeutic potential.